NR 546 FINAL EXAM CHAMBERLAIN PSYCHOPHARMACOLOGY – (2026) ACTUAL QUESTIONS AND
ANSWERS ALREADY GRADED A+| 100% VERIFIED SOLUTIONS………...
Core Domains
Neurobiology and Neurotransmitter Systems
Pharmacokinetics and Pharmacodynamics
Antidepressant Medications (SSRIs, SNRIs, TCAs, MAOIs, Atypicals)
Antipsychotic Medications (First-Generation, Second-Generation)
Mood Stabilizers and Anticonvulsants
Anxiolytics and Sedative-Hypnotics
ADHD and Stimulant Medications
Substance Use Disorders and Pharmacotherapy
Special Populations (Pregnancy, Pediatrics, Geriatrics)
Clinical Decision-Making and Adverse Effect Management
Introduction
This comprehensive examination is meticulously designed to evaluate your mastery of advanced
psychopharmacology principles essential for the Psychiatric-Mental Health Nurse Practitioner (PMHNP) role and
the NR 546 final examination at Chamberlain University. The exam assesses your understanding of neurobiology,
pharmacokinetics, medication selection, adverse effect management, and clinical decision-making across diverse
psychiatric disorders. Through a combination of multiple-choice and scenario-based questions, you will be
challenged to apply critical thinking and evidence-based practice to real-world patient care situations. Mastery of
,these competencies is imperative for demonstrating readiness for advanced psychiatric nursing practice. This
assessment mirrors the complexity and breadth of the official NR 546 final examination.
Section One: Questions 1 – 100
1. The monoamine hypothesis of depression suggests that depression is associated with:
A. Excess serotonin and dopamine
B. Deficiency of serotonin, norepinephrine, and dopamine
C. Overstimulation of glutamate and GABA receptors
D. Low acetylcholine and histamine
🟢B
🔴 RATIONALE: The monoamine hypothesis states that depression results from a deficiency in the monoamine
neurotransmitters: serotonin (5-HT), norepinephrine (NE), and dopamine (DA).
2. Which of the following is considered the primary mechanism of action of selective serotonin reuptake
inhibitors (SSRIs)?
A. Inhibit dopamine reuptake
B. Inhibit serotonin reuptake
C. Block norepinephrine receptors
D. Enhance GABA activity
🟢B
🔴 RATIONALE: SSRIs increase serotonin levels by inhibiting its reuptake in the synaptic cleft, thereby
enhancing mood regulation. Dopamine reuptake inhibition is targeted by other agents, norepinephrine
receptors are not blocked, and GABA enhancement is unrelated to SSRI mechanism.
,3. Before prescribing an SSRI, the most important screening includes:
A. Cardiac arrhythmias and kidney function
B. Bipolar disorder and suicidal ideation
C. Blood pressure and electrolyte levels
D. Alcohol use and smoking history
🟢B
🔴 RATIONALE: SSRIs can precipitate mania in patients with bipolar disorder and may increase suicidal
thoughts, especially in patients under 25. Screening for these conditions prevents adverse outcomes.
4. Adolescents and young adults under 25 taking SSRIs are at increased risk for:
A. QT prolongation
B. Suicidal ideation
C. Hypertensive crisis
D. Manic episodes
🟢B
🔴 RATIONALE: The FDA black box warning highlights an increased risk of suicidal thinking and behavior in
children, adolescents, and young adults under 25 taking SSRIs.
5. Which SSRI has the least CYP450 interactions and is considered safest in polypharmacy?
A. Fluoxetine
B. Escitalopram
C. Paroxetine
D. Fluvoxamine
🟢B
🔴 RATIONALE: Escitalopram has minimal CYP450 inhibition, making it the SSRI with the fewest drug-drug
interactions and the safest choice in polypharmacy.
, 6. Which SSRI has the longest half-life, reducing discontinuation syndrome risk?
A. Sertraline
B. Fluoxetine
C. Paroxetine
D. Citalopram
🟢B
🔴 RATIONALE: Fluoxetine has a half-life of 4-6 days and an active metabolite, norfluoxetine, making it long-
acting and protective against discontinuation syndrome.
7. Which SSRI is most associated with discontinuation syndrome if stopped abruptly?
A. Paroxetine
B. Fluoxetine
C. Escitalopram
D. Sertraline
🟢A
🔴 RATIONALE: Paroxetine has a short half-life and is most associated with discontinuation syndrome when
stopped abruptly, including symptoms such as dizziness, nausea, and headache.
8. What is the primary mechanism of action of bupropion?
A. Serotonin reuptake inhibition
B. Dopamine and norepinephrine reuptake inhibition
C. GABA receptor enhancement
D. Acetylcholine receptor blockade
🟢B
🔴 RATIONALE: Bupropion inhibits dopamine and norepinephrine reuptake, which aids in treating depression
and smoking cessation. It does not primarily target serotonin, GABA, or acetylcholine.
ANSWERS ALREADY GRADED A+| 100% VERIFIED SOLUTIONS………...
Core Domains
Neurobiology and Neurotransmitter Systems
Pharmacokinetics and Pharmacodynamics
Antidepressant Medications (SSRIs, SNRIs, TCAs, MAOIs, Atypicals)
Antipsychotic Medications (First-Generation, Second-Generation)
Mood Stabilizers and Anticonvulsants
Anxiolytics and Sedative-Hypnotics
ADHD and Stimulant Medications
Substance Use Disorders and Pharmacotherapy
Special Populations (Pregnancy, Pediatrics, Geriatrics)
Clinical Decision-Making and Adverse Effect Management
Introduction
This comprehensive examination is meticulously designed to evaluate your mastery of advanced
psychopharmacology principles essential for the Psychiatric-Mental Health Nurse Practitioner (PMHNP) role and
the NR 546 final examination at Chamberlain University. The exam assesses your understanding of neurobiology,
pharmacokinetics, medication selection, adverse effect management, and clinical decision-making across diverse
psychiatric disorders. Through a combination of multiple-choice and scenario-based questions, you will be
challenged to apply critical thinking and evidence-based practice to real-world patient care situations. Mastery of
,these competencies is imperative for demonstrating readiness for advanced psychiatric nursing practice. This
assessment mirrors the complexity and breadth of the official NR 546 final examination.
Section One: Questions 1 – 100
1. The monoamine hypothesis of depression suggests that depression is associated with:
A. Excess serotonin and dopamine
B. Deficiency of serotonin, norepinephrine, and dopamine
C. Overstimulation of glutamate and GABA receptors
D. Low acetylcholine and histamine
🟢B
🔴 RATIONALE: The monoamine hypothesis states that depression results from a deficiency in the monoamine
neurotransmitters: serotonin (5-HT), norepinephrine (NE), and dopamine (DA).
2. Which of the following is considered the primary mechanism of action of selective serotonin reuptake
inhibitors (SSRIs)?
A. Inhibit dopamine reuptake
B. Inhibit serotonin reuptake
C. Block norepinephrine receptors
D. Enhance GABA activity
🟢B
🔴 RATIONALE: SSRIs increase serotonin levels by inhibiting its reuptake in the synaptic cleft, thereby
enhancing mood regulation. Dopamine reuptake inhibition is targeted by other agents, norepinephrine
receptors are not blocked, and GABA enhancement is unrelated to SSRI mechanism.
,3. Before prescribing an SSRI, the most important screening includes:
A. Cardiac arrhythmias and kidney function
B. Bipolar disorder and suicidal ideation
C. Blood pressure and electrolyte levels
D. Alcohol use and smoking history
🟢B
🔴 RATIONALE: SSRIs can precipitate mania in patients with bipolar disorder and may increase suicidal
thoughts, especially in patients under 25. Screening for these conditions prevents adverse outcomes.
4. Adolescents and young adults under 25 taking SSRIs are at increased risk for:
A. QT prolongation
B. Suicidal ideation
C. Hypertensive crisis
D. Manic episodes
🟢B
🔴 RATIONALE: The FDA black box warning highlights an increased risk of suicidal thinking and behavior in
children, adolescents, and young adults under 25 taking SSRIs.
5. Which SSRI has the least CYP450 interactions and is considered safest in polypharmacy?
A. Fluoxetine
B. Escitalopram
C. Paroxetine
D. Fluvoxamine
🟢B
🔴 RATIONALE: Escitalopram has minimal CYP450 inhibition, making it the SSRI with the fewest drug-drug
interactions and the safest choice in polypharmacy.
, 6. Which SSRI has the longest half-life, reducing discontinuation syndrome risk?
A. Sertraline
B. Fluoxetine
C. Paroxetine
D. Citalopram
🟢B
🔴 RATIONALE: Fluoxetine has a half-life of 4-6 days and an active metabolite, norfluoxetine, making it long-
acting and protective against discontinuation syndrome.
7. Which SSRI is most associated with discontinuation syndrome if stopped abruptly?
A. Paroxetine
B. Fluoxetine
C. Escitalopram
D. Sertraline
🟢A
🔴 RATIONALE: Paroxetine has a short half-life and is most associated with discontinuation syndrome when
stopped abruptly, including symptoms such as dizziness, nausea, and headache.
8. What is the primary mechanism of action of bupropion?
A. Serotonin reuptake inhibition
B. Dopamine and norepinephrine reuptake inhibition
C. GABA receptor enhancement
D. Acetylcholine receptor blockade
🟢B
🔴 RATIONALE: Bupropion inhibits dopamine and norepinephrine reuptake, which aids in treating depression
and smoking cessation. It does not primarily target serotonin, GABA, or acetylcholine.
